An update on ODM-201 in the treatment of advanced prostate cancer

Posted on August 7, 2017 by Sitemaster

A while back now (in late 2014) Bayer initiated Phase III trials of the investigational agent ODM-201 — now also known as daralutamide — in the treatment of advanced prostate cancer. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: , , , , , | Leave a comment »

Time to death among men with nmCRPC by NCCN risk group

Posted on May 18, 2017 by Sitemaster

One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 20 Comments »

Current management of men with nmCRPC: a review

Posted on May 5, 2016 by Sitemaster

A new review article in the journal Oncology provides an excellent and relatively brief overview of the current options and recommendations for treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 5 Comments »

Astellas/Medivation initiate Phase III trial of enzalutamide in nmCRPC

Posted on December 3, 2013 by Sitemaster

According to a media release issued by Astellas Pharma and Medivation earlier today, the companies have initiated a new Phase III clinical trial to investigate the efficacy and safety of enzalutamide in the management of non-metastatic (TxNxM0), castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 2 Comments »